argenx SE/€ARGX
1D1W1MYTD1Y5YMAX
Capital at risk
About argenx SE
Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources:
- Argenx Official Website: www.argenx.com
- "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com
- Ticker
- €ARGX
- Sector
- Health
- Primary listing
- BSE
- Employees
- 1,863
- Headquarters
- Amsterdam, Netherlands
- Website
- argenx.com
argenx SE Metrics
BasicAdvanced
€54B
38.44
€22.53
-0.02
-
Price and volume
Market cap
€54B
Beta
-0.02
52-week high
€924.40
52-week low
€564.60
Average daily volume
80K
Financial strength
Current ratio
5.123
Quick ratio
4.524
Long term debt to equity
0.428
Total debt to equity
0.558
Interest coverage (TTM)
504.45%
Profitability
EBITDA (TTM)
1,386.451
Gross margin (TTM)
59.07%
Net profit margin (TTM)
32.26%
Operating margin (TTM)
30.13%
Effective tax rate (TTM)
1.81%
Revenue per employee (TTM)
€2,449,860
Management effectiveness
Return on assets (TTM)
11.63%
Return on equity (TTM)
23.63%
Valuation
Price to earnings (TTM)
38.441
Price to revenue (TTM)
11.729
Price to book
6.43
Price to tangible book (TTM)
6.64
Price to free cash flow (TTM)
69.004
Free cash flow yield (TTM)
1.45%
Free cash flow per share (TTM)
12.553
Growth
Revenue change (TTM)
70.30%
Earnings per share change (TTM)
39.82%
3-year revenue growth (CAGR)
85.31%
10-year revenue growth (CAGR)
80.64%
3-year earnings per share growth (CAGR)
54.19%
10-year earnings per share growth (CAGR)
37.57%
Bulls say / Bears say
VYVGART’s commercial momentum is strong: second-quarter 2026 product net sales reached $1.5 billion, up 60% year over year and 17% sequentially. The May 2026 FDA label expansion to all adult gMG serotypes materially broadens the addressable U.S. population. (argenx)
ALKIVIA produced a statistically significant Phase 3 result in autoimmune myositis, including a significant result in immune-mediated necrotizing myopathy, a subtype for which argenx noted there was no approved targeted therapy. This could support VYVGART’s expansion beyond neuromuscular disease into rheumatology. (argenx)
argenx is building additional growth engines beyond VYVGART: empasiprubart is in registrational studies for multifocal motor neuropathy and CIDP, with MMN data expected in the fourth quarter of 2026, while management expects ten molecules in clinical development by year-end. (argenx)
Revenue remains heavily concentrated in VYVGART: argenx reported $2.813 billion of product net sales in the first half of 2026, while VYVGART is its primary commercial product. This concentration increases exposure to pricing, reimbursement, safety, competition, and execution risks around one franchise. (argenx)
The positive ALKIVIA result was not uniformly decisive: although the combined autoimmune-myositis population met the primary endpoint, the dermatomyositis subgroup did not achieve statistical significance. That leaves regulatory and label-expansion uncertainty in an important new indication. (argenx)
The Forte Biosciences acquisition adds pipeline potential but also introduces integration, capital-allocation, and clinical-development risks; argenx specifically disclosed risks that the transaction could divert management attention and that Forte’s programs may not deliver expected results. (argenx)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
Funds containing argenx SE
AllEURGBPUSD
Fund name | Fund size | €ARGX weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 3.35% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 2.88% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 2.88% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.35% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.35% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.